Brooks Laboratories Share Price Today | Stock Price & Brooks Laboratories Share Screener
As of October 5, 2026, the live Brooks Laboratories share price (NSE: BROOKS) is ₹54.24 on NSE and ₹54.68 on BSE, down 1.02% from the previous close, with shares trading between ₹53.65 and ₹55.88 in today's trading session, and a 52-week range of ₹37.11–₹121.61. Check BROOKS price range for the annual price range and momentum. Use the Brooks Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Brooks Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹22 and net income of ₹2, with EBITDA of ₹2, an operating margin of 3.0% and a profit margin of 9.1%.
Brooks Laboratories Share Price Chart
Track the current stock price of Brooks Laboratories with an interactive chart. Analyse BROOKS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Brooks Laboratories stock quote in one place.
The quote of ₹54.24 sits between the 52-week low of ₹37.11 and the 52-week high of ₹121.61, and the latest session moved -1.02% from the previous close.
Brooks Laboratories Company Profile - Fundamental Screener
Screen Brooks Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BROOKS shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE650L01011.
Company Details
Classification
Identifiers and Leadership
Brooks Laboratories Balance Sheet Screener
Screen BROOKS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹148, up from ₹124 in 2025.
Latest statistics put total assets at ₹148 and shareholder funds at ₹123, with a leverage ratio of 0.08.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
Assets |
||||||
| Total Assets | 148 | 124 | 90 | 110 | 196 | 162 |
| Current Assets | 37 | 34 | 31 | 28 | 61 | 47 |
| Fixed Assets | 15 | 14 | 14 | 15 | 110 | 108 |
Liabilities |
||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 4 | 3 | 2 | 3 | 13 | 19 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||
| Total Equity | 123 | 98 | 66 | 74 | 134 | 79 |
| Share Capital | 30 | 30 | 26 | 25 | 25 | 25 |
| Reserves & Surplus | 93 | 69 | 39 | 49 | 63 | 54 |
Brooks Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Brooks Laboratories income statement and profit fundamentals. Analyze BROOKS quarterly results. Brooks Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹22 and net profit was ₹2, equal to earnings per unit of ₹0.52, at an operating margin of 3%.
In that period expenses were ₹20, interest cost ₹0 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹23 and net profit of ₹-2.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 22 | 23 | 24 | 33 | 30 | 22 | 18 | 18 | 21 | 21 | 13 | 16 | 24 | 22 | 29 |
| Expenses | 20 | 24 | 25 | 22 | 21 | 16 | 27 | 20 | 24 | 22 | 16 | 20 | 25 | 25 | 32 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 2 | -1 | -1 | 10 | 9 | 6 | -9 | -2 | -3 | -2 | -4 | -4 | -1 | -3 | -4 |
| Operating Profit % | 3.00% | -6.00% | -5.00% | 12.00% | 11.00% | 4.00% | -54.00% | -11.00% | -16.00% | -7.00% | -29.00% | -25.00% | -5.00% | -15.00% | -14.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 2 | -2 | -1 | 10 | 8 | 6 | -10 | -2 | -4 | -2 | -4 | -5 | -2 | -4 | -7 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Net Profit | 2 | -2 | -2 | 10 | 8 | 6 | -10 | -2 | -4 | -2 | -4 | -5 | -2 | -4 | -6 |
| EPS | 0.52 | -0.61 | -0.54 | 3.25 | 2.71 | 1.87 | -3.77 | -0.94 | -1.51 | -0.82 | -1.75 | -1.81 | -0.60 | -1.51 | -1.46 |
Brooks Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen BROOKS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹9, and net cash flow was an inflow of ₹7.
Over the same period, investing activities used ₹3 and financing activities provided ₹0.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||
| Operating Activities | 9 | 3 | -10 | -15 | -37 | 5 |
| Investing Activities | -3 | -45 | 0 | 1 | -25 | -5 |
Financing and Net Cash | ||||||
| Financing Activities | 0 | 42 | 10 | 11 | 64 | 1 |
| Net Cash Flow | 7 | 0 | 0 | -3 | 2 | 1 |
Brooks Laboratories Shareholding Pattern Screener
See Brooks Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Brooks Laboratories promoter holding and ownership changes for BROOKS on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 52.62%, foreign institutions 0.17%, domestic institutions 10.38% and the public 31.56%, spread across 10,741 shareholders.
The shareholder count was 10,741 in 2026-Mar, compared with 11,161 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Jan | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 63.59% |
Institutional Investors | ||||||||
| FII Holding | 0.17% | 0.00% | 0.00% | 0.05% | 0.00% | 0.01% | 0.09% | 0.00% |
| DII Holding | 10.38% | 10.38% | 9.90% | 10.38% | 10.38% | 10.38% | 10.38% | 3.86% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.56% | 30.73% | 32.13% | 31.86% | 32.01% | 31.70% | 31.84% | 25.55% |
| Other Holding | 5.28% | 6.27% | 5.35% | 5.08% | 4.99% | 5.30% | 5.07% | 7.00% |
| Shareholder Count | 10,741 | 11,161 | 10,374 | 10,537 | 10,317 | 10,078 | 10,532 | 11,432 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Brooks Laboratories. Brooks Laboratories dividend yield can be compared with peers and other stocks in the market.
Brooks Laboratories Stock Index Membership - Nifty & Sensex
See which indices include Brooks Laboratories stock. Check BROOKS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Brooks Laboratories Market Events Screener - Corporate Actions
Get Brooks Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Brooks Laboratories stock events that may affect BROOKS share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 3, 2026, with a record date of September 3, 2026.
It is followed by Quarterly Result Announcement dated August 13, 2026 and Quarterly Result Announcement dated May 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-03 | 2026-09-03 | Annual General Meeting | NA | 6.74% |
| 2026-08-13 | 2026-08-13 | Quarterly Result Announcement | NA | 3.27% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 21.52% |
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | -4.59% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 3.90% |
| 2025-09-26 | 2025-09-26 | Annual General Meeting | NA | -5.83% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -4.69% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -3.00% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -12.64% |
| 2025-01-11 | 2025-01-11 | Extraordinary General Meeting | NA | 15.99% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -4.13% |
| 2024-09-19 | 2024-09-19 | Annual General Meeting | NA | 25.21% |
| 2023-09-21 | 2023-09-21 | Annual General Meeting | NA | 6.27% |
| 2023-07-28 | 2023-07-28 | Rights | 1:16 | 12.52% |
| 2020-02-11 | Rights | 9:20 | - |
Brooks Laboratories Competitors Screener - Peer Stocks Comparison
Screen BROOKS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 440,998 | 36.70 | 61,674 | 12.69% | 11,565 | 40.74 |
| Divis Laboratories | 253,522 | 87.22 | 11,067 | 13.95% | 2,568 | 63.87 |
| Torrent Pharmaceuticals | 185,201 | 87.95 | 13,886 | 20.34% | 2,138 | 46.50 |
| Zydus Life Science | 122,257 | 26.11 | 27,658 | 17.64% | 5,026 | 66.57 |
| Cipla | 111,782 | 33.64 | 29,045 | 2.24% | 3,870 | 45.42 |
| Laurus Labs | 108,549 | 99.16 | 6,868 | 22.01% | 890 | 64.04 |
| Dr Reddys Laboratories | 101,913 | 31.54 | 35,059 | 3.90% | 4,158 | 63.11 |
| Mankind Pharma | 100,589 | 49.45 | 14,636 | 14.85% | 1,938 | 55.24 |
| Aurobindo Pharma | 97,670 | 26.54 | 34,145 | 5.56% | 3,503 | 54.66 |
| Lupin | 94,281 | 17.22 | 29,039 | 26.75% | 5,356 | 35.30 |
Brooks Laboratories Company Announcements - News & Reports Screener
Screen BROOKS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 29, 2026.
The next most recent announcements are dated September 16, 2026 and September 16, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-29 | Closure of Trading Window | - |
| 2026-09-16 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-09-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-04 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-03 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-21 | Addendum To The Notice Of 24Th Annual General Meeting Of The Company. | - |
| 2026-08-21 | Reg. 34 (1) Annual Report. | - |
| 2026-08-17 | Intimation Of Record Date E-Voting Dates And Book Closure Date | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-13 | Results - Financial Results For June 30 2026. | - |
| 2026-08-13 | Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday 13Th August 2026 | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-12 | Letter To The Shareholders - Annual Report For The FY 2025-26. | - |
| 2026-08-12 | Shareholder Meeting- AGM On 3Rd September 2026. | - |
| 2026-08-12 | Reg. 34 (1) Annual Report. | - |
| 2026-08-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-06 | Board Meeting Intimation for Under Regulation 29 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) | - |
| 2026-07-17 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-07-16 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹54.24, within a 52-week range of ₹37.11 to ₹121.61. The P/E ratio is 13.13 and the P/B ratio is 1.42, with earnings per unit of ₹8.35. Market capitalisation stands at ₹166.58 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 5, 2026. This page covers 6 balance sheet periods, 15 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.